October 23, 2026; By Benjamin Kosubevsky
Turning 40 doesn’t flip a switch in your body. But your 40s are when many people first face real decisions about heart health, and it’s a good time to ask whether three markers that aren’t on a standard panel make sense for you: ApoB, hs-CRP, and fasting insulin.
Each one answers a different question:
None of them is a diagnosis on its own. Together, they can fill in parts of the picture that a standard cholesterol panel and glucose test don’t show.
Current cholesterol guidelines estimate heart risk for adults as young as 30, using the American Heart Association’s PREVENT calculator for ages 30 to 79 (American Heart Association). Treatment decisions often start in the 40s, though. The U.S. Preventive Services Task Force recommends a statin for adults 40 to 75 who have at least one cardiovascular risk factor and a 10-year risk of 10% or higher (USPSTF). Blood sugar screening overlaps this window too, starting at 35 for adults with overweight or obesity (USPSTF).
When your risk falls somewhere in the middle, guidelines point to “risk-enhancing factors” that can help tip the decision. Two of the markers in this article are on that list in the 2026 ACC/AHA dyslipidemia guideline: an ApoB of 120 mg/dL or higher, and an hs-CRP of 2 mg/L or higher on more than one test (UIC Drug Information Group summary of the 2026 guideline).
Fasting insulin isn’t on that list. It may offer an early clue about insulin resistance, but it isn’t a guideline-backed risk factor.
A standard lipid panel measures how much cholesterol is in your blood. ApoB measures something slightly different: how many particles are carrying it.
Every particle that can deposit cholesterol in your artery walls, including LDL, carries exactly one apolipoprotein B (ApoB) molecule. That makes ApoB a count of those particles (Endotext, NCBI Bookshelf).
Most of the time, ApoB and LDL cholesterol tell the same story. Studies generally find ApoB is more closely tied to heart risk than LDL cholesterol, and the difference matters most when the two disagree. That mismatch is more common in people with high triglycerides, diabetes, obesity, or metabolic syndrome (Endotext, NCBI Bookshelf).
The 2026 ACC/AHA dyslipidemia guideline treats an ApoB of 120 mg/dL or higher as a risk-enhancing factor, and it sets ApoB treatment goals for some people, with lower targets for those at higher risk (UIC Drug Information Group). It also treats ApoB as a selective test rather than one for everyone. It says ApoB can help refine risk and guide treatment once LDL and non-HDL cholesterol goals are met, particularly for people with high triglycerides, diabetes, or LDL already below 70 mg/dL (American Heart Association).
C-reactive protein (CRP) is made by your liver when there’s inflammation in your body. The standard CRP test looks for larger amounts, like those caused by an infection. The high-sensitivity version, hs-CRP, picks up much lower levels and is used to help estimate heart disease risk (Mayo Clinic).
A 2003 scientific statement from the American Heart Association and CDC groups hs-CRP results into three ranges: below 1 mg/L is lower risk, 1 to 3 mg/L is average, and above 3 mg/L is higher risk (AHA and CDC Scientific Statement). The 2026 ACC/AHA dyslipidemia guideline counts 2 mg/L or higher on more than one test as a risk-enhancing factor, if it’s measured (UIC Drug Information Group).
Two caveats matter here. First, hs-CRP isn’t specific to your heart. Obesity, smoking, diabetes, infections, and injuries can all raise it (StatPearls, NCBI Bookshelf). Second, the 2003 statement says it may help most when heart risk falls in a gray zone, and that it shouldn’t be used to screen everyone (AHA and CDC Scientific Statement).
Fasting glucose and A1c show where your blood sugar is. Fasting insulin shows how much effort it takes to keep it there.
With insulin resistance, your cells respond less to insulin, so your pancreas releases more to compensate. For years, that extra insulin can hold glucose in a normal range while the underlying problem grows. Insulin resistance is thought to begin 10 to 15 years before type 2 diabetes develops (StatPearls, NCBI Bookshelf).
Pairing fasting insulin with fasting glucose makes it possible to calculate HOMA-IR, an estimate of insulin resistance widely used in research. That said, there’s no generally accepted test for insulin resistance, and these measures aren’t part of clinical guidelines (StatPearls, NCBI Bookshelf). NIDDK notes that formal insulin resistance testing is used mainly in research (NIDDK).
So I don’t treat fasting insulin as a diagnosis. I treat it as an early signal, one worth reading alongside everything else.
Insulin resistance is closely tied to higher triglycerides, lower HDL, and smaller, denser LDL particles, and it’s linked to heart disease, stroke, and circulation problems in the legs (StatPearls, NCBI Bookshelf). That lipid pattern is also where ApoB and LDL cholesterol most often disagree (Endotext, NCBI Bookshelf). Metabolic syndrome, also called insulin resistance syndrome, raises the risk of heart disease, diabetes, and stroke (NHLBI). And conditions that tend to travel with insulin resistance, like obesity and diabetes, are linked to chronic low-grade inflammation that can show up as a higher hs-CRP (StatPearls, NCBI Bookshelf).
That’s why I like to look at all three together. A single high number is a clue. A pattern across all three gives your provider more context.
| Marker | What it measures | What a high result can signal | Where it stands in guidelines |
|---|---|---|---|
| ApoB | The number of particles that can deposit cholesterol in artery walls | More plaque-building particles than LDL alone may show | Risk-enhancing factor at 120 mg/dL or higher (2026 ACC/AHA) |
| hs-CRP | Low-grade inflammation | Inflammation linked to heart risk, though not specific to the heart | Risk-enhancing factor at 2 mg/L or higher on more than one test (2026 ACC/AHA) |
| Fasting insulin | How much insulin it takes to control fasting blood sugar | A possible early sign of insulin resistance | Not part of clinical guidelines |
A few details make these numbers more reliable:
The encouraging part is that the drivers behind these markers often respond to changes you and your provider can make.
Which of these changes fits you, and whether medication belongs in the plan, is a decision to make with your provider based on your full picture.
At The Longevity Center FL, one of the physician-owned practices managed by Longevity Centers of America (LCOA), these three markers are part of a bigger conversation, not a standalone test.
We start with your history, your family history, and your goals, and that shapes which markers make sense to test. When results come back, your provider walks through them with you and connects them to the rest of your health history. From there, you and your provider decide on next steps, which may include repeat testing to see how your numbers change over time.
If you’re over 40 and wondering whether these markers fit your situation, schedule a consultation to talk it through.
ApoB is a protein found on every particle that can deposit cholesterol in your artery walls, including LDL. Because each particle carries one ApoB, the test reflects how many of these particles you have. Studies generally find ApoB is more closely tied to heart risk than LDL cholesterol, especially when the two disagree.
There isn’t one target that fits everyone. The 2026 ACC/AHA dyslipidemia guideline treats an ApoB of 120 mg/dL or higher as a risk-enhancing factor, but a lower number isn’t automatically ideal, and the guideline sets lower ApoB goals for some people at higher risk. Your provider interprets your result alongside your LDL cholesterol, triglycerides, and overall heart risk.
Below 1 mg/L is considered lower risk, 1 to 3 mg/L average, and above 3 mg/L higher risk, according to a 2003 statement from the American Heart Association and CDC. The 2026 ACC/AHA dyslipidemia guideline also treats 2 mg/L or higher on more than one test as a risk-enhancing factor. Because infections, injuries, and other conditions can raise it, it’s best measured twice, about two weeks apart, when you’re otherwise healthy.
Fasting insulin isn’t part of clinical guidelines, and there’s no generally accepted test for insulin resistance. Your provider reads fasting insulin alongside fasting glucose, A1c, and your overall health rather than against a single number.
You’ll need to fast overnight for fasting insulin. ApoB and hs-CRP can be drawn fasting or not. We’ll give you specific instructions before your blood draw.
Current cholesterol guidelines estimate heart risk starting at age 30, but your 40s are when many people first face treatment decisions. The U.S. Preventive Services Task Force recommends a statin for adults 40 to 75 with at least one cardiovascular risk factor and a 10-year risk of 10% or higher. Markers like ApoB and hs-CRP can help refine risk when it falls in the middle.
Often, the things that drive them can change. Physical activity improves how your muscles respond to insulin, and for people at high risk, losing 5 to 7% of starting weight helped reduce the chance of type 2 diabetes. Diet, activity, and weight loss can lower LDL cholesterol, and statins can lower it further. When hs-CRP runs high, obesity, smoking, and diabetes are usually the first things I look at. Your provider can help you decide what fits.
From Lab Results to a Longevity Roadmap: How to Decide What to Address First
When Standard Bloodwork Looks Normal but You Still Don’t Feel Right
ApoB, hs-CRP, and Fasting Insulin: Three Biomarkers Worth Understanding After 40
What a Longevity Blood Panel Can Reveal Beyond a Routine Physical
The Evidence for Stellate Ganglion Block Has Caught Up With the Anecdotes
